Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 683 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Dermata Therapeutics, Inc.
Market Cap
$4.52M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.64M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$4.53M
Debt to Equity Ratio
0.90
TTM Avg
0.35
3Y Avg
0.23
5Y Avg
0.29
Market Cap
$4.86M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$4.38M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.21M
Debt to Equity Ratio
0.18
TTM Avg
0.73
3Y Avg
0.52
5Y Avg
0.35
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | $4.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| CalciMedica, Inc. (CALC)vs › | $4.63M | 0.00 | 0.00 | 0.00 | 0.92 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | 0.00 | 0.00 | 0.02 | 0.02 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.53M | 0.90 | 0.35 | 0.23 | 0.29 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.86M | 0.02 | 0.03 | 0.03 | 0.03 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | 0.18 | 0.73 | 0.52 | 0.35 |
| Imunon, Inc. (IMNN)vs › | $5.13M | 1.87 | 0.21 | 0.18 | 0.20 |
| GRI Bio, Inc. (GRI)vs › | $4.15M | 0.00 | 0.02 | 0.03 | 0.03 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | N/A | 0.02 | 0.03 | 0.02 |
Debt/Equity
0.00
Current Ratio
2.81
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | -0.35 |
| 2021-03-31 | 0.25 |
| 2020-12-31 | -1.12 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
